DBV Technologies S.A.: DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years : vimarsana.com

Montrouge, France, September 7, 2022 DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7

Related Keywords

Colorado , United States , Montrouge , France General , France , Australia , Canada , United Kingdom , French , American , Anne Pollak , Angela Marcucci , Pharis Mohideen , David Fleischer , Exchange Commission , Company Adss , Ethics Committee , Drug Administration , Modified Viaskin Peanut Patch , Allergic Children Ages , Institutional Review Board , Stock Market , Viaskin Peanut Patch , Institutional Review Boards , Ethics Committees , Colorado Children , Principal Investigator , Viaskin Peanut , Daniel Tass , Chief Executive Officer , Chief Medical Officer , Cumulative Reactive Dose , Complete Response Letter , Biologics License Application , North American , Basking Ridge , Euronext Paris , Nasdaq Global Select Market , Des March , Technologies , Nnounces , Nitiation , Hase , Tudy , Itesse , Sing , Odified , Iaskin , Eanut , Atch , Llergic , Hildren , Ges , Ears ,